Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation.
Liang-Tseng KuoSu-Ju LinVictor Chien-Chia WuJung-Jung ChangPao-Hsien ChuYung-Lung ChenPublished in: Therapeutic advances in musculoskeletal disease (2021)
Different direct oral anticoagulants had different impact on osteoporotic fracture Anticoagulation therapy is an essential therapy in atrial fibrillation (AF) patients, but osteoporotic fracture is another important issue in these patients prescribed with anticoagulants. However, no study has been conducted to evaluate the impact of different DOACs on different types of osteoporotic fractures. In our findings, although different DOACs had no significantly different impact on osteoporotic fractures, dabigatran users had a slightly higher incidence of osteoporotic and hip fractures among different DOACs, particularly in those have simultaneously had peripheral artery disease, a history of hip fracture. In addition, when AF patients taking low-dose DOACs, dabigatran users also have higher incidence of hip fracture than those taking other DOACs.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- hip fracture
- end stage renal disease
- low dose
- oral anticoagulants
- left atrial
- catheter ablation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- left atrial appendage
- bone mineral density
- prognostic factors
- heart failure
- high dose
- peritoneal dialysis
- stem cells
- coronary artery disease
- risk factors
- mesenchymal stem cells
- bone marrow
- cell therapy
- mitral valve